A user underwent a hair transplant at Moart Clinic in Seoul, receiving 1100 grafts in the crown area after Dutasteride and oral Minoxidil failed to improve a stubborn bald spot. The procedure was successful, with minimal pain and good post-op recovery, costing $6900 USD before a tax refund.
A person shared their hair regrowth journey using HIMS topical treatments with finasteride, minoxidil, hormone replacement therapy (HRT), and microneedling. They also discussed their transition as a transgender woman and the positive impact of HRT on hair recovery.
The conversation discusses a hair loss treatment regimen involving dutasteride, pyrilutamide, oral minoxidil, and microneedling, with the aim of suppressing DHT and stimulating hair growth. Users debate the effectiveness and potential side effects of these treatments, noting that individual results may vary and that no treatment is foolproof.
The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.
The conversation is about someone who initially had positive results with Minoxidil for hair loss, lost those gains due to a hospital stay, and is now not seeing the same results upon resuming treatment. They plan to add microneedling and/or tretinoin to their regimen and are seeking success stories from others who did not respond to Minoxidil alone.
Topical dutasteride, especially at higher concentrations, can be effective for hair loss when combined with microneedling to enhance absorption. Users discuss the side effects of finasteride and dutasteride, with some preferring topical treatments to avoid systemic side effects.
Pelage is developing a topical hair follicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.
Hair loss after telogen effluvium (TE) with thinning and possible scarring, treated with 5 mg oral minoxidil. Concerns about scarring alopecia and lack of regrowth, with suggestions to consider finasteride for better results.
The conversation discusses the theory that scalp fibrosis contributes to male pattern baldness (MPB) by increasing DHT concentration, and mentions treatments like Minoxidil. The user seeks opinions on the theory and the effectiveness of scalp massages.
The conversation is about the anticipation of results for a hair loss treatment study, specifically for GT20029, with expectations for the results to be released in the first quarter of 2024. No specific treatments were discussed.
A user shared their hair regrowth success using microneedling with a dermaroller every 6 days and minoxidil, recommending betadine (povidone-iodine) before microneedling to sterilize the scalp and enhance results. Another user noted the potential risks of iodine toxicity.
The conversation humorously discusses hair loss treatments, mentioning scalp massage, minoxidil, and the ineffectiveness of devices like the "Gr0wBand." It highlights the role of androgens in hair loss and suggests that increased blood flow from massage may not significantly impact hair growth.
A user beginning to take Pyrilutamide as a treatment for their hair loss, and other users sharing their experiences with the drug or similar treatments such as Minoxidil, Finasteride, and RU58841.
The conversation is about a nearly 10-month hair loss treatment regimen that includes 1mg finasteride daily, topical minoxidil twice daily, 1.5mm microneedling once or twice a week, and Nizoral shampoo 2-3 times a week. Users are supportive and inquire about the effectiveness of microneedling.
The conversation is about whether castor oil can be effectively used alone after microneedling without a penetration enhancer like DMSO or ethanol. The user believes microneedling-induced wounds might be enough for absorption.
The conversation discusses GT20029, a drug in Phase II trials that targets androgen receptors with minimal systemic effects, and TDM-105795, a growth stimulant with a different mechanism than minoxidil that may revive papilla stem cells. Both are potential new treatments for hair loss.
A user was prescribed betamethasone dipropionate spray for a receding hairline, which caused skin peeling and depigmentation. They stopped using it and are considering alternatives like BPC-157/TB-500 for healing.
The user is experiencing a second hair shedding phase and increased flaking and itching while using minoxidil 5% nightly and microneedling every two weeks, with needle length increasing over time. Other users suggest the hair loss may continue without the use of finasteride.
Microneedling combined with minoxidil and finasteride initially showed significant hair growth, but stopping microneedling and reducing minoxidil use led to hair loss. Returning to the original routine may help regain lost progress.
The conversation discusses hair loss treatments, specifically topical dutasteride, minoxidil, and finasteride. Users share experiences and opinions on the effectiveness and side effects of these treatments.
The conversation discusses the effectiveness of dutasteride injections for hair loss, often paired with oral minoxidil and oral finasteride/dutasteride. The user is seeking information on U.S. clinics offering this treatment.
The user shared progress pictures showing improvement in hair growth after one year of using finasteride and minoxidil. They are considering microneedling to further improve their hairline and have chosen to use a derma stamp.
User regrew lost hair using microneedling, minoxidil, finasteride, Nizoral, fish oil, and collagen peptide. Progress was slow but constant, and patience was important.
Pyrilutamide is a selective AR antagonist with a high binding affinity, making it effective in competing with DHT for androgen receptors. The 1% concentration is more effective than the 0.5%, but the latter may suffice for mild hair loss; the drug is considered a good option for those avoiding 5AR blockers due to side effects.
User experienced hair loss after weight lifting, had a successful hair transplant, but later faced significant thinning. Current treatment includes finasteride, minoxidil, dermal rolling, and supplements.
A new topical medication, Clascoterone, shows promise for hair loss, improving hair count significantly. Trials for Breezula are ending, but sign-ups for PP405 trials are available for 2026.
The user is asking if the hair regrowth achieved from microneedling can be maintained by just using finasteride after stopping microneedling. They used microneedling to enhance the effects of finasteride on hair growth.
The user is considering a hair transplant and is using topical finasteride, minoxidil, antiandrogens, ketoconazole shampoo, and serenoa repens. They are deciding between surgeons Dogan Turan and Bruno Pinto, and are concerned about the technique and potential complications due to diffuse hair loss.
The user is experiencing hair regrowth after two months using topical finasteride, minoxidil spray, and weekly microneedling. They report less hair loss and stronger hair growth.